Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

319.20 1.91 −0.59%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
79.72 77.20 74.97 68.03

+8 more quarters

P/S ratio
8.04 8.26 8.87 8.62
P/FCF ratio
62.62 57.55 60.62 69.17
P/Operating CF
302.19 269.64 148.29 139.91
P/B ratio
7.92 8.12 8.75 8.48
EV/Sales
7.62 7.83 8.46 8.25
EV/EBITDA
56.79 57.64 60.25 56.00
EV/FCF
59.36 54.59 57.83 66.17
Current Ratio
5.89 5.75 6.02 6.64
Net Debt/EBITDA
(11.65) (13.70) (13.91) (8.23)
Debt/Equity
0.01 0.01 0.01 0.01
Earnings Yield
1.25% 1.30% 1.33% 1.47%
Free Cash Flow Yield
1.60% 1.74% 1.65% 1.45%
Free Cash Flow per Share
0.67 0.83 1.87 1.75
Book value per Share
40.19 38.90 37.53 36.68
Free Cash Flow
26.40 32.54 73.30 68.05
EV/EBIT
62.82 62.92 65.74 61.17
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026